Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534093 | 0.83 | AURKA (0.53) | AURKAAURKBCHEK1CDK2CCNA2 | |
| SCHEMBL13899597 | 0.82 | AURKA (0.43) | AURKAAURKBCHEK1CDK2CCNA2 | |
| SCHEMBL14529991 | 0.80 | CHEK1 (0.64) | AURKAAURKBCHEK1CDK2CCNA2 | |
| SCHEMBL8246082 | 0.80 | CHEK1 (0.64) | AURKAAURKBCHEK1CDK2CCNA2 | |
| SCHEMBL14530381 | 0.79 | AURKA (0.56) | AURKAAURKBCHEK1CDK2CCNA2 | |
| SCHEMBL13954940 | 0.78 | AURKB (0.81) | AURKAAURKBCHEK1CDK2LCK | |
| SCHEMBL14542649 | 0.76 | CHEK1 (0.66) | CHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL8429700 | 0.73 | AURKA (0.63) | AURKAAURKBCHEK1 | |
| SCHEMBL14534233 | 0.73 | AURKB (0.45) | AURKAAURKBCHEK1CDK2LCK | |
| SCHEMBL14534020 | 0.72 | AURKB (0.42) | AURKAAURKBCHEK1CDK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKA 5/4885AURKB 24/4885CHEK1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.